Vidofludimus Calcium: meta-analysis of COVID-19 studies

All studies   Mortality   Ventilation   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 220 patientsc19early.org

Vidofludimus Calcium for COVID-19

Serious outcome risk
Vidofludimus Calcium
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)0%
Mortality (1)0%
Ventilation (1)0%
RCTs (1)0%
Late (1)0%
00.511.5+
← Vidofludimus
Calcium
reduces riskIncreased
risk →
c19early.org
October 2026

Vidofludimus calcium COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Vehresch.. (DB RCT)0%1.00 · 0.14–6.97death2/1102/110
Late treatment0%1.00 · 0.14–6.972/1102/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.14–6.972/1102/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Vidofludimus
Calcium
reduces riskVidofludimus
Calcium
increases risk →
c19early.org
October 2026

Vidofludimus calcium COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Vehresch.. (DB RCT)0%1.00 · 0.14–6.972/1102/110
Late treatment0%1.00 · 0.14–6.972/1102/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.14–6.972/1102/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Vidofludimus Calcium
reduces riskVidofludimus Calcium
increases risk →
c19early.org
October 2026

Vidofludimus calcium COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Vehresch.. (DB RCT)0%1.00 · 0.33–3.016/1106/110
Late treatment0%1.00 · 0.33–3.016/1106/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.33–3.016/1106/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Vidofludimus Calcium
reduces riskVidofludimus Calcium
increases risk →
c19early.org
October 2026

Vidofludimus calcium COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Vehresch.. (DB RCT)0%1.00 · 0.14–6.97death2/1102/110
Late treatment0%1.00 · 0.14–6.972/1102/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.14–6.972/1102/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Vidofludimus
Calcium
reduces riskVidofludimus
Calcium
increases risk →
c19early.org
October 2026

Vidofludimus calcium COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Vehresch.. (DB RCT)0%1.00 · 0.14–6.97death2/1102/110
Late treatment0%1.00 · 0.14–6.972/1102/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.14–6.972/1102/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Vidofludimus
Calcium
reduces riskVidofludimus
Calcium
increases risk →
c19early.org
October 2026

Vidofludimus calcium COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Vehresch.. (DB RCT)0%1.00 · 0.14–6.972/1102/110
Late treatment0%1.00 · 0.14–6.972/1102/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.14–6.972/1102/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Vidofludimus Calcium
reduces riskVidofludimus Calcium
increases risk →
c19early.org
October 2026

Vidofludimus calcium COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Vehresch.. (DB RCT)0%1.00 · 0.14–6.97death2/1102/110
Late treatment0%1.00 · 0.14–6.972/1102/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.14–6.972/1102/1100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Vidofludimus
Calcium
reduces riskVidofludimus
Calcium
increases risk →